spacer
home > ebr > Winter 2011
PUBLICATIONS

European Biopharmaceutical Review

ebr
Winter 2011

   
Text
PDF
BioBusiness, Finance & Communication
Partnering is the lifeblood of the biotech and pharmaceutical industries and, as the industry expands, Robert Lee Kilpatrick from TVG discusses the ideal elements for successful collaborations.
 
view
download pdf
Neil Johnson, Ad Rietveld and Chloë Brown of RJW & Partners Ltd consider the benefits of thorough in-licensing evaluation and early understanding of payers' perspectives in guaranteeing launch success.
 
view
download pdf
bullet
Discovery Technology
Xavier Tizon at Oncodesign makes a strong case for the untapped potential of imaging biomarkers and how they can be applied in future drug development stages.
 
view
download pdf
Simon Webster from Avacta Group PLC considers the benefits of maintaining physical stability of candidate therapeutic proteins at an early stage in the discovery process, and highlights pioneering techniques for monitoring conformational and colloidal stability.
 
view
download pdf
bullet
BioDevelopment and Regulatory
For companies facing up to the move from proof-of-concept to proof-of-differentiation, Markus Thunecke from Catenion considers the three levels of evaluation that should be considered.
 
view
download pdf
Kai Lamottke at Bicoll GmbH, Christophe Ripoll at Naturalpha and Robert Walczak at Genfit SA consider if natural product programmes are ready to challenge the traditional drug cycle process.
 
view
download pdf
By encouraging others to develop their own drugs using a patented technology, the patent owner has the potential to develop substantial revenues, observe Michael R Ward,Otis Littlefield and Anita Choi from Morrison & Foerster LLP.
 
view
download pdf
Sekhar Medisetti at GlobalData takes a look at the niche market for Type 1 diabetes, the continuous challenge posed by patient compliance, and the problematic issue of delivery methods for insulin products.
 
view
download pdf
bullet
BioFormulation and Manufacturing
Bill Whitford of Thermo Scientific Cell Culture and BioProcessing analyses the advantages of single-use bioreactors and the supply and performance features they offer in process development.
 
view
download pdf
In response to the danger posed by bacterial retention testing, Martha Folmsbee, Morven McAlister and Jerold Martin at Pall Life Sciences compare and contrast the various tests for predicting and confirming retention.  
view
download pdf
Amin Omar at Innovotech highlights the need for finding the most suitable antimicrobial agent to avoid the potential problems of biofilm infections.
 
view
download pdf
bullet
BioRegional
Following the launch of the Smart SME Market Validation Programme, Rebecca Philpot from the State Government of Victoria, Australia, considers other ways in which the city is changing to better accommodate the biotech industry.
 
view
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July, and October

News and Press Releases

Sphere Fluidics introduces latest version of Cyto-Mine Studio Software Suite

Cambridge, UK, 27 August 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis. The latest software version includes new functionality to further enhance users’ workflows in biologics discovery and cell line development.
More info >>

White Papers

Inhaler Adherence: Exploring Key Factors

Aptar Pharma

Aptar Pharma recently hosted an expert panel roundtable on “Inhaler Adherence”. This international scientific forum was held in Paris, France on November 29th 2013. The roundtable was organized to explore and exchange views on the issues which may influence inhaler adherence/ compliance with a particular focus on asthma and C.O.P.D. therapies and their corresponding inhaler devices (MDIs, DPIs).
More info >>

Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement